CareRx Corporation

For Q2 2026, CareRx reported revenue of $93.6 million, up from $91.4 million in Q2 2025. Adjusted EBITDA was $8 million, unchanged year over year, with adjusted EBITDA margin at 8.6% versus 8.8% a year ago. Net income was approximately $400,000 compared with $600,000 in the prior-year quarter, and cash from operations was $3.7 million versus $3.8 million last year. Average beds serviced increased to 91,719 from 90,048. On the balance sheet, cash was $9.6 million at June 30, 2026, net debt was $29.1 million, and net debt to adjusted EBITDA was 0.9x. For guidance/commentary, management still expects the Ontario ward-bed funding change to be about a $2 million full-year revenue impact, with full Q2 effect and recovery only as ward rooms are redeveloped; the newly won 3,000 beds are being onboarded in Q3 and should contribute fully in Q4.

Puneet Khanna described the quarter as consistent operationally and financially, emphasizing that results were helped by new beds added during the prior year and by cost savings initiatives, partly offset by Ontario ward-bed funding changes. He highlighted the new 3,000-bed contract as a milestone that validates CareRx’s service quality, clinical expertise, resident safety, and technology differentiation. His tone was upbeat but measured, repeatedly pointing to a strong pipeline, ongoing efficiencies, and continued organic growth opportunities.

Suzanne Brand focused on the financial bridge: revenue growth came mainly from higher average beds serviced, while the Ontario funding change weighed on revenue, EBITDA margin, and net income. She cited adjusted EBITDA of $8 million, margin of 8.6%, net income of approximately $400,000, and cash from operations of $3.7 million, alongside cash of $9.6 million, net debt of $29.1 million, and leverage of 0.9x net debt to adjusted EBITDA. She also noted $1.3 million of dividends paid after quarter-end and said the higher dividend rate fits the company’s balanced capital allocation priorities of growth, balance sheet strength, and shareholder returns.

Analysts focused on three main topics: the Ontario ward-bed funding headwind, the new 3,000-bed contract, and the outlook for bed growth and margins. Management reaffirmed the $2 million full-year hit from ward-bed funding, said roughly $667,000 of the impact was seen in Q2, and stated the full recovery will come only as affected homes redevelop rooms, likely not completed in 2026 and more likely late 2027. On the new contract, management said onboarding started immediately and will be complete before the end of Q3, with the full EBITDA benefit showing in Q4; they also said the contract covers the client’s whole portfolio, spans Ontario and Western Canada, and offers margin contribution in line with current business. Management added that the 6,000 to 8,000 bed-addition target remains organic and that the pipeline remains strong, while semaglutide-related margin benefits are expected to be more meaningful in 2027 due to supply variability.